CITE-seq is a powerful technique that helps detect gene and protein expression in a single cell. By gathering information from both omes, CITE-seq helps to unlock deeper insights about your samples and can reveal novel cell types and different cell states.

We offer a complete CITE-seq solution with a streamlined sample-to-data workflow. BD^® AbSeq Antibody-Oligo reagents allow you to build your own custom CITE-seq panels or you can use our pre-designed BD^® OMICS-One Protein Panels, that make CITE-seq on the BD Rhapsody^™ System even more accessible. Optimized, validated and designed to target key immune cell markers, these panels let you explore activation and suppression states of your immune cell samples with ease at a reduced sequencing cost.

Talk to one of our specialists about bringing BD^® OMICS-One Protein Panels to your lab.

SMART Panel Design Lowers Sequencing Cost While Preserving the Sensitivity and Resolution of CITE-Seq Data 

CITE-seq experiments with antibody-oligos traditionally incur high sequencing costs because highly abundant protein targets such as CD45 and CD44 consume most of the sequencing reads requiring deeper sequencing to detect less abundant secondary and tertiary protein targets. SMART panel design addresses this challenge by utilizing carefully selected, pre-titrated concentrations of antibody-oligos against abundant primary markers. This helps to distribute sequencing reads to the more critical secondary and tertiary targets without compromising the sensitivity or ability to detect the abundant cell surface primary markers.

How does this work? Select antibody-oligos in each BD^® OMICS-One Protein Panel that target select, highly expressed primary markers are titrated and lyophilized alongside “cold antibodies” (antibodies lacking oligonucleotides) of the same clone. This approach generates a gradual and predictable decrease in reads allocated to the primary marker targeted thereby moderating the signal of the targeted marker without affecting the ability to resolve cell populations. The outcome is better resolution of low-expressed proteins at the same sequencing depth without incurring additional sequencing costs.